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ABSTRACT 
Introduction: Malaria parasite resistant to Chloroquine poses severe and increasing health problems in 
tropical countries. Monitoring the drug resistance by implementing the molecular markers may be essential 
to overcome the problem, therefore this study aims to assess the Chloroquine resistance of Plasmodium 
Falciparum parasite in central Sudan, using molecular markers. 
Methods: One hundred and seventy six patients were confirmed P. falciparaum positive. Sixty-four were 
selected and only forty patients completed the follow-up. In vivo sensitivity assay was used accompanied 
with standard regimen of Chloroquine phosphate. DNA was extracted from blood on filter paper (day 0) 
and was used to amplify two genes P. Falciparum transporters gene Pfcrt and multi-drug resistant gene-1 
Pfmdr-1. 
Results: Among forty patients, 54% responded to Chloroquine regimen with adequate clinical response 
(ACR), however, 46% showed treatment failure. All treatment failures were treated with Artemether or 
Quinine. The amplification of Pfcrt gene (n, 18) and Pfmdr 1 gene (n, 29), had shown that 72% of Pfcrt 
T76 were mutant allele, 22% were K76 wild-type, however, only 5% were mixed alleles T/K. while Pfmdr 
1 gene (n, 29) revealed that 55% were wild genotype N 86, 38% were mutant Y 86, and 7% were mixed 
alleles Y/ N 86. 
Conclusion: The high frequency of the mutant Pfcrt 76T gene among P. 
 
 
Falciparum isolates was consistent with in vivo study supports the hypothesis that Pfcrt 76T gene could be 
used as predictive marker for Chloroquine susceptibility in epidemiological surveys.  
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ةصلاخلا 
 نيوكرولكلل ةمواقملا ايرلاملا لكشتارطخ  آيمانتميف نأف كلذل , ةيرادملا لودلا مادختسا  ىف ) ةيئيزجلا تامسوملا(ءاصقتسا  ليفطلا ةمواقم
لكشت دق نيوكرولكلا راقعل  ةيمهأيف  ةساردلا هذه تفده. ةلكشملا هذه ىلع بلغتلاءاصقتسلا ةمواقم  )مرابسلف مويدومزلاب(ليفطلا راقعل
 نادوسلا طسو ىف نيوكرولكلامادختساب تامسوملا ةيئيزجلا.   مت ،صحفلل نوبجوم مهنأ دكأت نوعبسو ةتس ةئام ةساردلا هذه تلمشرايتخا 
ةعبرأ ةعباتم ةقيرط تمدختسا .لاماك مهتعباتم تمت نوعبرأ طقف ،ةساردلا هذهل مهنم نوتسو  اقبط ضيرملا لخاد يف ليفطلا ةيساسح
يقلا ةعرجللمتو نيوكرولكلا تافسوفل ةيسا  صوقنم يزوبيارلا يوونلا ضمحلا صلاختسانيجسكلأاDNA)  ذخأ مد اهب حيشرت ةقرو نم)
لبق  .ضيرم لكل جلاعلا ءدبتمدختساو ةمواقملا تارفطلا راشتنا يدم ديدحتو مييقتل  مويدومزلابلا ليفط تاثروم نم نينثا يف نيوكرولكلل
مرابسلاف PFCRT K76T) و   (PFMDR.1 N86Y  يلسلسلا لعافتلا زاهج مادختسابتاميزنلإاو يوونلا ضمحلل ةعطاقلا   .    تلمش
 باجتسا ،اضيرم نوعبرأ ةساردلا هذه54% مل امنيب جلاعلل مهنم  بجتسي54 % نيذلا ىضرملا لك جلاع متو جلاعلل مهنم  اوبيجتسي مل
نينيكلا وأ رثيمترلاا راقعب جلاعلل.  يثارولا حسملا يرجأ(رملبلا يلسلسلا لعافت مادختساب تارفطلل(PCR تاميزنلإاو  ضمحلل ةعطاقلا
يوونلا (RFLP) نيثروملل (Pfcrt) ( اهددع81و ) (Pfmdr-1) ( اهددع92دجوو )  نأ29%  نيج نم (Pfcrt) تارفط لمحت 
(T76) نيجلل (Pfcrt)  نأو99% ثروملاب (K76 Pfcrt)  نأ دجو امنيب4% ا نم طيلخ تارفط لمحترفاطلا ريغو رفاطلا ليللا  
(K/T76) نيجلل يثارولا حسملا ةجيتن تحضوأ (Pfmdr-1 Y86N)  نأب81% تارفط لمحت  نأو44%  ةرفط لمحت لا تايليفطلا نم
 نأو هل2%  لمحت تايليفطلا نم .رفاطلا ريغو رفاطلا ليللاا نيجلأ نم طيلخ رفاطلا نيجلا راركت ةدايز نأ ةساردلا تصلخ (Pfcrt 
76T)تايليفط يف  ةيضارتفا ززعت مرابسلاف مويدومزلابلاةيناكمإ نيج مادختسا (Pfcrt 76T)  مسوميساسأ  ةيساسح ةفرعمو ةبقارمل
راقعل مرابسلاف مويدومزلابلا ليفط ةمواقم يف نيوكرولكلل ةيئابولا تاحوسملا.  
INTRODUCTION 
Resistance to Chloroquine was noted in Thai-Cambodian border and in Colombia since the late 1950s (1), 
whereas in Africa, the chloroquine resistance was first reported in east of Africa in 1978 and the resistance 
spread to centre and south of the continent and at last to the west of Africa 1983, and by 1989 chloroquine 
resistance was wide spread in Sub-Saharan Africa (2). 
Polymorphism in two genes of Plasmodium falciparum (P.falciparium) genome had contributed in 
chloroquine resistance. The P. facibarum chloroquine resistance transporters (Pfcrt) gene located in 
chromosome 7 and this segment harbors a 13-exon, Pfcrt, having point mutations that associate completely 
with chloroquine resistant (CQR) in parasite lines from Asia, Africa, and South America (3),  
Laboratory studies in Cameroon and Mali have strongly suggested that P. falciparum chloroquine resistance 
transporter (Pfcrt Lys76Thr) gene can be used as a marker in surveillance for chloroquine-resistant 
falciparum malaria as a molecular marker (4-6). In diverse geographical areas several studies support the 
association between the Pfcrt K76T and chloroquine resistance in Africa (Mali) (5), Sudan (7-9), Nigeria 
(10), Gabon (11), Gambian (12), Malawi (13), Liberia (14), Tanzania (15), Mozambique (16), Ghana (17), 
Camroon (18) and Senegal (19-20). Asia Thailand (21) and India (22), and Amazon region Brazil (23, 24), 
however studies from Uganda at the south gate of Sudan reported no association (25). 
Initial studies of the gene P. falciparum Multidrug resistance gene (Pfmdr-1) located on chromosome 5, 
illustrate that an Asn→Tyr mutation at amino acid 86 (N86Y) and other mutations in this gene correlated 
with chloroquine resistance in {Sudan (7), Mali (5), Gambia (12), Uganda (27), Brazil and Thailand (21)}, 
however, some authors from {Uganda (28), Brazil (29), and Thailand (30)}, could not find this correlations 
in their studies.  
 
MATERIAL AND METHODS 
Patients: This study was conducted in Marengan Health Center and 48 patients with positive P. Falciparum 
bloods were enrolled in the study. 
The In vivo study: 
Chloroquine phosphate (AMIPHARMA Laboratories Ltd. Sudan B N/T0013) was administrated orally at 
a dose of 10 mg per kilogram (kg) of body weight in day (0) and 5 mg per kg body weight after 6 hours, 
and in day 1 and day 2, the patients were observed after each dose, and they were given another full dose 
or a half dose if vomiting occured within 30 min or within 31 min to 1 hour respectively. Clinical and 
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parasitological follow-up was done on day 1, 3, 7 and 14. Whenever symptoms were reported or parasiteima 
increased, the case is considered as in vivo Chloroquine resistance state (31) and alternative treatment was 
scheduled for that.  
Assessment of in vivo response and implementing molecular techniques:  
This was done according to WHO assessment (31). Blood samples were obtained on white man filter paper 
0.3 immediately before treatment and stored in 4Cº, DNA was extracted from filter paper blood samples by 
cutting an approximately 4 mm2 piece of paper was placing in 100 ìl methanol, air dried, and incubated at 
95 to100 ºC in 50 μl of water for 15 minutes. During incubation, the tube was subjected to high-speed 
vortex three times. 5 μl of resulting solution used as template for PCR (5) 
The PCR reaction was performed in 30 μl volumes which contains 1X PCR Buffer II (Gene Amp® 10X 
Buffer II [100 mM Tris-HCl pH 8.3, 500 mM KCl], Applied Bio system), 1.5 mM MgCL2 (MgCl2, Applied 
Bio system), 0.2 mM each of the dNTP (Gene Amp® dNTPs, Applied Bio system), 1.0 μ mol of each sense 
and antisense primers 1 U of AmpliTag Gold (Applied Bio system), 5 μl of the Template DNA; and the 
reaction volume was completed to 30 μl by ddH2O. 
Nested PCR for the detection of tyr-86 allele of pfmdr-1 in field isolates for all reactions was amplified 
using Gene Amp® PCR system 9700 (Applied Bio system) in the following conditions: one cycle at 94 ºC 
for 3 minutes; 40 cycles at 94 ºC for 1 minute, 49 ºC for 1 minute, and 72º C for 1 minute; and a final 
extension at 72º C for10 minutes was carried out using outer primers MdrA1 and. MdrA3 (32). 3 μl were 
used for the second round as a template of nested PCR, with anew set of inner primers Mdr A2 and Mdr 
A4 without change in the PCR condations as described by (32). A nested PCR protocols were used to 
identify the K76T in the Pfcrt gene (3) with a slight modification on primers used to amplify in Gene Amp® 
PCR system 9700 (Applied Bio system). The outer primers tcrp- 1 and Pfcrt-13 in the following conditions: 
one cycle at 94º C for 3 minutes; 40 cycles at 94 ºC for 30 seconds, 55 ºC for 30 seconds, and 60º C for 30 
seconds; and a final extension at 60 ºC for 3 minutes. 2 μl of product was diluted 1/20 and 3 μl were used 
as a template for the nested reaction using Pfcrt-14 and Pfcrt-15 primers in the following conditions: one 
cycle at 94 ºC for 3 minutes; 40 cycles at 92 C for 30 seconds, 49 ºC for 30 seconds, and 65 ºC for 30 
seconds; and a final extension at 65 ºC for 3 minutes. For each series of samples, water was used as a 
negative control, HB3-strain DNA was used as the wild-type control, and Dd2 DNA was used as the mutant 
control. All the amplifications were checked using agarose gel electrophoresis, in which PCR products were 
run in 1.5 %( Pfmdr-1 gene) and 2 %( Pfcrt gene). 
Comparing gene sequence in group of individuals; change in one or more base pairs occur causing variation 
in the sequence, these variations are called polymorphisms, furthermore, restriction site may be created or 
abolished at that point, this is known as Restriction Fragment Length Polymorphism (RFLP) (33) .  The 
mutations in the tow genes Pfcrt and Pf mdr-1 have been abolished by the restriction site for Apo 1 enzyme 
(Fig 2.4). Digestion with this enzyme was used for typing these polymorphisms. In a total volume of 15 µl, 
2 µl PCR product were digested overnight at 50°C with 1 U Apo I, 1.5 µl 10x NE Buffer 3 (100 mM Nacl, 
50 mM Tris-Hcl,10 mM magnesium chloride and 1mM dithiothreitol (pH 7.9 @ 25 °C), 0.15 µl of 100X 
BSA (200μg/ml ) and deionized water. Using the Genomic DNA from strain 3D7 and Dd2 were Amplified 
and digested in the same way serving as control for complete digestion, and undigested fragment 
respectively (Fig. 2.1). 
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Study area: The study was conducted at Marengan Health Center Medani, Sudan, from September to 
December 2002, where the malaria incidence is high. 
Patients: Patients with symptoms or signs suggesting malaria were screened for the presence of malaria 
parasites in their peripheral blood. One hundred and seventy six (176) patients were found to be smear 
positive for malaria; 94% of them were infected with P. falciparum; 6 % with mixed infection P. falciparum 
and P. vivax or P. vivax only. 
Sixty four (64) patients fulfilled the criteria for selection and enrolled in the study; and only 40 patients 
were completed the period of follow up.  
Response of P. falciparum isolates to chloroquine according to in vivo test: 
Fig (2) shows the adjustment of isolates to chloroquine according to WHO standard regimen dose and 
selection criteria. From forty (40) patients treated with chloroquine, only 22 (54%) responded fully with 
adequate clinical and parasitological response (ACR), in 18 (46%) patients drug resistance was found 
distributed to 9 (23%) with early treatment failure (ETF) and 9 (23%) with late treatment clinical and 
parasitological failure (LTF). All the treatment failures were treated with artemether injection 1.6 mg/ Kg 




Table 1 shows the distribution of the mean parasitemia and the standard error of in vivo test. According to 
sensitivity all the 22 (54%), the group of ACR, with mean initial parasitemia, 20089 ± 6520, 5723 ± 2713, 
and 00 ± 00 in D0, D1, and D3 respectively.  Finally, only one patient was found to have severe malaria 
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The prevalence of Pfcrt T76 and Pfmdr 1 mutations:  
Fig. (3) Presented the pattern of detection of P. falciparum chloroquine resistance transporter gene (Pfcrt) 
using nested PCR method where as, (Fig. 4) shows the detection of P. falciparum multi-drug resistance 1 
gene using nested PCR method. (Fig. 5), represented the pattern of restriction fragment length 
polymorphism (RFLP) of Pfmdr 1 gene. The prevalence of Pfcrt T76 and Pfmdr 1 Y86 was screened in 18 
and 29 parasite isolates respectively. Restriction fragment length polymorphism (RFLP) technique using 
Apo 1 enzyme was used for screening the isolates. Table 2 shows that the Pfcrt T76 mutation was present 
in 13 (72%) samples, 4 (23%) had the wild-type of Pfcrt K76 and only one (5%) sample with mixed alleles 
of wild and mutant (T76K). and the prevalence of Pfmdr-1 Y86 was present in 11 (38%) mutant type and 
16 (55%) were found to be Pfmdr 1 N86 and 2 (7%) carried the mixed alleles of wild and mutant type 
(Y86N) in (Table 3.). 
 
Figure.3.: Detection of of P. falciparum chloroquine resistance transporter gene (Pfcrt) using nested PCR method. 
 
 
In vivo Sensitivity Number  Mean ± (S. E. M) 
D0       ACR 
            ETF 
            LTF 
 
D1       ACR 
            ETF 
            LTF 
 
D3       ACR 
            ETF 
            LTF 
 
D7       ACR 
            ETF 
            LTF 
 
D14      ACR 
            ETF 




















20089 ± 6520 
22550 ± 6532 
16230 ± 7083 
 
5723 ± 2713 
3530± 1180 
5388 ± 3934 
 
00 ± 00 
1869 ± 1093 
00 ± 00 
 
00 ± 00 
- 
1015 ± 541 
 
00 ± 00 
- 
400 ± 00 
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Fig. 4: Detection of of P. falciparum multi-drug resistance 1 gene using nested PCR method. 
Lane 1: M: 100-bp DNA marker. Lane 2: PCR product (positive control). Lanes 3 -11 Positive amplification (502 bp) PCR 
products and lane 12 negative control. 
 
 
Figure.5: PCR-RFLP screening of P. falciparum isolate for codon 76 polymorphism. Lane 1and 10: DNA markers. 
Lane 2: digested PCR product (positive control). Lane 3&5: K76 polymorphism (cutted by Apo1 restriction enzyme to145 and 
64 bp). Lane 4, 6, 7, 8&9: T76 polymorphism (uncutted full length 209 Pb). 
 
 
Figure.6: PCR-RFLP screening of P. falciparum isolate for codon 86 polymorphism 
Lane 1: Mixed infection by two strains carring both hapoliod alleles N86 and Y86 Lane 2, 4 & 7: N86 allele (cutted by 
Apo1 restriction enzyme to 254 and 248 bp) Lanes 3, 5, 6 & 8: Y86 allele (uncutted by Apo1 restriction enzyme full 




Association of mutations and treatment outcome:  
In (Table 2) six samples were classified as ACR according to in vivo sensitivity test, the molecular 
technique shows three samples had K76, two of samples had T76 (the mutant type), and the last one with 
mix alleles T76 and K76. In eight isolates classified as ETF using in vivo test, the molecular techniques 
showed only one sample (12.5%) which had the wild type K76 and the rest of the isolates (87.5%) carring  
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the mutant one T 76. In the isolates classified as LTF all isolates (100%) had the mutant type T76. No 
sample in treatment failure outcome of Pfcrt gene was observed to have mixed alleles. 
Pfmdr 1 gene mutation represented in (Table. 3) no sample in the group, which classified as ACR of Pfmdr-
1 gene was observed to have mixed alleles and only two isolates with mixed alleles in isolate classified as 
ETF were found. 
Frequency of Pfcrt and Pfmdr 1 genotypes among P. falciparum isolates:  
The distribution P. falciparum isolates according to Pfmdr-1 and Pfcrt genotypes were illustrated in (Fig.7) 




























Pf Mdr-1 marker 1 P = 0.005  
In vivo sensitivity P = 0.000 
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In vivo assessment:  
In this study, the failure rate for treatment during in vivo assessment of sensitivity to chloroquine was 46%, 
this is very remarkable because the similar failure rate was reported in Sudan (34), and also similar 
Frequencies (39-46%) were observed in other African countries (35-38) . 
 According to the recent classification of WHO criteria for in vivo drug sensitivity into ACR, ETF and LTF 
(31) , the results distributed as follows; 22 patients (54%) were ACR, 9 patients (23%) ETF and 9 patients 
were LTF (23%). (Fig. 2). 
In (ACR) group, the isolates with low or moderate levels of resistance, the infection could be resolved and 
cured due to many factors that could be summarized in a proper drug dose, parasites genetic material and 
partial immunity experiences, this more evident in full immune response patients in endemic areas (39). In 
case of the (ETF) and (LTF) there are many factors contributing to the treatment outcome; factors that 
influencing host and parasites; in case of host the main factors are immune status of the patients, for the 
Isolate    In vivo Pfmdr 1 Pfcrt 
C10 ACR ND ND 
C11 ACR ND ND 
C12 ETF Y T 
C13 ACR N K 
C15 ACR N ND 
C16 ETF N T 
C19 ACR N ND 
C20 ACR N ND 
C21 LTF ND ND 
C22 ETF ND ND 
C23 ETF Y T 
C24 ACR N K 
C25 ACR Y ND 
C27 ACR N ND 
C28 ACR N ND 
C29 LTF N T 
C30 LTF Y T 
C31 ACR ND ND 
C33 ETF Y ND 
C34 ACR ND ND 
C35 ACR ND ND 
C36 ACR ND ND 
C37 ACR ND ND 
C38 ETF N K 
C40 ETF N/Y T 
C41 ACR Y ND 
C42 ETF N T 
C43 ACR Y T 
C44 ACR N ND 
C46 LTF Y T 
C47 LTF Y ND 
C48 ETF N/Y T 
C49 LTF N T 
C50 ACR N/Y T/K 
C51 LTF N ND 
  C/2R LTF ND ND 
 C5/R LTF Y T 
C52 ACR N K 
C53 







Total 40 29 18 
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parasites the mutations, which affect drug action, the interaction between sexual stage and the vectors and 
moreover, the environment may alter in this process (1, 40-42) , all these factors may allow the parasites to 
survive in the presence of chloroquine.  
In general, residents of malaria-endemic areas sometimes spontaneously clear P. falciparum infection 
without drug treatment, implying an important role for host factors, such as immunity, in this clearance 
(43). 
The effect of the initial parasitemia on the treatment outcome:  
Comparison of the effect of the initial parasitemia on the treatment outcome showed no significant 
difference in chloroquine response at different levels of the initial parasitemia (Table 1), this indicates that; 
the initial parasitemia has no role in determining the chloroquine in vivo response. This finding was in line 
with study done in Sennar (44) , however, study done by Wernsdorfer et al, observed higher mean initial 
parasitemia in the group of resistance parasites, than in sensitive one (45). 
Molecular markers:   
P. falciparum Chloroquine resistance transporter (Pfcrt):  
Characterization of genes controlling drug resistance in parasite, as in dihydrofolates reductease gene lead 
to the development of molecular markers, this is used for proper diagnosis and early detection of treatment 
failure (46).  
The prevalence of Pfcrt T76 mutations (the mutations which was incriminated in chloroquine resistance) 
was present in 78% of our isolates, and 22% (4 isolates) carring the wild type of Pfcrt K76 (Fig. 7), most 
of the isolates with mutation type might have been resistant in vivo, however, 34% and 14% of the mutant 
alleles T76 and T/K76 were recovered by immune response and classified as ACR ( Table 2), this find 
indicated the important role of the host immunity, this observation was consistent with a number of studies 
(28, 43, 47). 
Most of the isolates classified as in vivo resistance, carrying Pfcrt T76, so based on this above observation; 
we strongly associated the subsequent resistance to chloroquine in vivo with the presence of Pfcrt T76, at 
the time of treatment. These data, are in line with genetic evidence of Fidock etal (3), on the other hand, 
only one isolate was detected carrying the wild type K76, and classified as in vivo resistance (Table 2). The 
possible explanation is that the patient had mixed infections with low level of resistant parasites carrying 
the mutant type, under the drug pressure the sensitive parasites were eliminated and the resistant ones 
expanded resulting in treatment failure. The presence of Pfcrt T76 at the time of treatment was also strongly 
associated with subsequent resistance to chloroquine in vivo.  
P. Falciparum multi drug resistance-1 gene (Pfmdr-1):  
The prevalence of the wild type of Pfmdr-1 isolates is more, compared to the mutant type in the screened 
samples (Fig. 3), indicating the less sensitivity of Pfmdr-1 for detecting the resistance isolates predicted by 
in vivo test. 
Among ACR group, the N86 can predict 71% of the sensitivity in vivo (Table 3), in the resistance group 
50% of isolates carrying the mutant type Y86. This observation is consistent with some other studies in 
which decrease in association between Pfmdr- 1 Y86 and sub-mutations and chloroquine resistance in vivo 
was reported (48, 49) 
Recently, many investigators showed that resistant infections in vivo can be due to parasites with no Pfmdr-
1 mutations at position Y86 and gave strong evidence to the link of this resistance to other gene (3, 5, 10). 
Chloroquine resistance in Sudan was first reported In the Gezira area (50), and then in Sennar (51) and 
Gadarif (52), but now resistance to chloroquine was reported in different parts of the country. In the last 
decade progress has been done in the molecular basis of drug resistance in P. falciparum. As more 
information on the genetics of anti-malarial resistance becomes available, designing of new molecular-
based tools for drug resistance evaluation, and applying them in early detection of drugs resistant will help 
in proper selection of antimalarial drugs and rapid treatment of patients which is the corner stones in malaria 
control. 
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